Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria

Hiroki Kawano, Kentaro Minagawa, Kanako Wakahashi, Yuko Kawano, Akiko Sada, Toshimitsu Matsui, Hirotaka Hirano, Hideyuki Shiomi, Yonson Ku, Yoshio Katayama

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) makes patients susceptible to intravascular hemolysis and thrombosis, and it can be life-threatening in stressful situations. Eculizumab, a humanized monoclonal antibody that inhibits the complement protein C5, has been evaluated as a novel therapy for PNH. We herein describe the case of a 59-year-old Japanese woman with classic PNH, who had been successfully treated with eculizumab, but who later developed acute cholecystitis/cholangitis from gallstones. Although the severe obstructive jaundice requiring endoscopic therapy following cholecystectomy was complicated, critical intravascular hemolysis and thrombosis were not observed. Therefore, utilizing eculizumab during the peri-operative management of PNH patients should be carefully taken into consideration.

Original languageEnglish (US)
Pages (from-to)2613-2616
Number of pages4
JournalInternal Medicine
Volume51
Issue number18
DOIs
StatePublished - 2012

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria'. Together they form a unique fingerprint.

Cite this